Tag Archives: Investors

RESI on MaRS Panel Announcement: Diagnostics Investors

29 Mar

By Claire Jeong, Research Analyst, LSN

claire

The field of diagnostics can be a difficult space to navigate due to challenges in the regulatory and reimbursement processes that hinder successful commercialization. However, the implications of diagnostic technologies can be enormous; from precision genomics that enable optimum health management and personalized care to novel biomarkers that can successfully detect high mortality diseases in its earliest stages, diagnostics companies are developing some of the most highly disruptive technologies in the industry.

In this session, we invite 5 investors with strong expertise in this diverse space to speak about their unique approaches in working with early-stage companies. Investors will discuss the types of investment opportunities they seek and share valuable insights on building long lasting relationships, differentiating your technology from similar competitors, and more. We hope you will be able to join us for the RESI Toronto Conference in the MaRS Innovation Center on April 10th to meet these awesome panelists!

Moderated by Drew Taylor, Lead Medical Researcher, Epic Capital Management, the panel participants are:

  • Yiu-Lian Fong, Innovation Lead for Diagnostics, Johnson & Johnson (Medical Devices)
  • Kelly Holman, Co-Founder & Managing Director, Genesys Capital
  • Yvan Côté, General Manager of Dynacare Next & Orchid PRO-DNA, Dynacare
  • Amine Benmoussa, Principal (Healthcare), BDC Healthcare Fund

 

RESI on MaRS Panel Announcement: Medical Device Investors

22 Mar

By Lucy Parkinson, VP of Investor Research, LSN

Medical device innovation is known for being a challenging area for raising capital.  Given the timelines and capital requirements involved, as well as the increasing consolidation of the major firms that make up the exit landscape for devices, entrepreneurs may find it difficult to build their investment story.  However, LSN is in contact with hundreds of investors who are seeking deals in the device space, either for purely return-driven investments or for adding to a strategic pipeline.  At RESI, we aim to bridge the gap between early stage device firms and investors and help entrepreneurs close those ‘last three feet’ to make deals.

At RESI on MaRS, we welcome a Medical Device Investors panel featuring experienced investors from across North America, including both strategic players and financially-driven venture investors who will explore and elucidate the world of early stage device investment from every angle.  The panel will be moderated by Sam Ifergan, President & CEO, iGan Partners, and the participants are:

  • Katherine Parra Moreno, Vice President of Business Development, Epic Capital Management
  • Zishan Haroon, Chairman and General Partner, Julz Co LLC
  • V Kadir Kadhiresan, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Gerry Brunk, Managing Director, Lumira Capital

China-Based Investors are Looking West for New Products in Diabetes Care

8 Mar

By Jessica Yang, Investor Research Analyst, LSN

Diabetes mellitus is a global epidemic, with the metabolic syndrome and cardiovascular risk factors believed to underlie the disease on the increase worldwide. Among this large diabetes market, China has a higher number of diabetics than any other country. According to a World Health Organization estimate, of all adults with diabetes, one in three is from China.

This attracts a large number of Chinese investors to investments in diabetes care. For example, in 2017, when Johnson & Johnson began evaluating whether to sell its diabetes units, including glucose meters, insulin pumps and other equipment used in diabetes care, multiple Chinese investors expressed interest in buying some or all of these business units. However, many Chinese investors are looking at early stage products in this space. LSN is in touch with nearly a hundred China-based firms that are open to considering pre-approval products in the diabetes and metabolic disease field.

Chinese investors have invested, in-licensed, acquired or formed joint ventures with multiple Western diabetes care companies in recent years – the investors are expecting to extract extra value from the diabetes market in China. According to Franck Le Deu, Hong Kong-based senior partner at McKinsey, it is possible that a Chinese company could extract more value from these technologies than a multinational since they have different expectations of profitability. Even with lower margins, a tremendous growing diabetes population makes the Chinese diabetes market very significant. In addition, Chinese investors could leverage its local capabilities and knowledge to help these companies’ growth in the country.

As Chinese investors are seeking Western technologies and startups to address the diabetes market in China, it is a great time for diabetes startups to consider building connections and working with these investors.

%d bloggers like this: